Global Vasculitis Market Research and Forecast 2018-2023Posted by Orion Market Research on July 17th, 2018 Vasculitis involves a range of conditions, such as Kawasaki disease and IgA Vasculitis that destroys the blood vessels (including small, medium and large). It is generally defined as inflammation within blood vessels. It affects essential body organs, such as lungs, kidneys and intestine. Moreover, the condition can affect any age group whether older, adults or children. For example, IgA Vasculitis are usually common in the children before age seven, however it can affect any age group. The Vasculitis market comprising diagnostic tests that are used by medical professionals to assess the patients’ condition and severity of the disease. It includes blood tests, imaging tests, biopsy, biopsy and angiography. Other tests comprising ANCA tests, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR). These tests are mainly used in a range of medical specialties, including diagnostic centers, research institutions, hospitals and clinics. Moreover, Anti-neutrophil cytoplasmic antibodies (ANCA) are one of the major vasculitis diseases affecting 7 to 10 people per million annually in the US (as per kidney International Reports 2018). As a consequence, it is providing the growth opportunity for the vasculitis market. Some companies are working to develop novel drugs and diagnostic tests for the effective treatment and more accurate detection of this disease. For example, In Feb 2017, Inova Diagnostics, a provider of autoimmune diagnostic reagents and systems for clinical laboratories has received approval for its products, named NOVA Lite DAPI ANCA (Formalin) and NOVA Lite DAPI ANCA (Ethanol) kits. These kits are the first FDA cleared reagents for ANCA detection on IFA microscope. It is highly useful for laboratories carry out ANCA IFA testing. It is a remarkable step towards standardizing and automating the ANCA IFA testing along with offering highly reliable test results to the clinicians. Moreover, the test results can be effectively uploaded into the patient’s EMR (electronic medical records). These features can help in faster and accurate reporting. Browse full report at: Global Vasculitis Market However, the drugs that are used in the treatment of ANCA include glucocorticoids, cyclophosphamide and autoimmune drugs (rituximab). More ANCA drugs are expected to be launched in the market soon. For example, In July 2018, InflaRx NV, a biopharmaceutical company has gained US FDA investigational new drug approval for the commencement of phase II trial of the IFX-1 drug. It is intended for the treatment of ANCA associated vasculitis. More companies such as GlaxoSmithKline Plc and Hoffmann-La-Roche Ltd. are also involved in the development of ANCA-associated vasculitis drug (AAV), which is creating scope for new potential drugs to be launched in near future. Their currently available products for the treatment of vasculitis condition include Nucala (mepolizumab) and Actemra/RoActemra (tocilizumab). Nucala (mepolizumab), a drug by GlaxoSmithKline Plc has approved by FDA for the treatment of adult patients suffering from eosinophilic granulomatosis with polyangiitis (EGPA). It is an autoimmune disease that causes vasculitis. EGPA patients usually suffer from frequent recurrence that increases the risk of permanent organ and tissue damage. Nucala (mepolizumab) is the first targeted drug which is approved for the treatment of this disease. The approval of this drug for EGPA is replied on the trial outcomes. It has represented that a 300mg dose of the antibody is delivered once in a month. This allows patients to decrease the utilization of oral corticosteroid therapy. Related Reports: Healthcare Industry Research Additionally, In Jan 2017, Actemra/RoActemra (tocilizumab), a drug by Hoffmann-La-Roche Ltd) has received a biological license application for the treatment of giant cell arteritis (GCA). It is a form of vasculitis. There has been no approved therapies available for GCA since more than 50 years. The approval is based on the successful result of its phase III GiACTA study while assessing Actemra/RoActemra in GCA affected people. According to the company, the product will be able to meet the patient’s unmet needs. There are some organizations supporting to overcome the challenge by providing funding to the companies for R&D purpose. For example, the Vasculitis Foundation (VF) funds researches globally to discover the cause as well as develop better treatment for vasculitis. The maximum awards provided will be of ,000 for 1 year. However, some grants will be available for 2 years with a maximum amount of ,000 annually. VF provides funds for following VF researches:
Such funding encourages R&D efficiency of companies, which helps the vasculitis market to grow further. Like it? Share it! More by this author |